
Commentary|Videos|September 10, 2025
Navigating Novel IO Regimens and ADCs in Lung Cancer With Drs Rodriguez, Olazagasti, and Roy
Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Advertisement
Coral Olazagasti, MD, and Estelamari Rodriguez, MD, MPH, both of the University of Miami Sylvester Comprehensive Cancer Center, and Tina Roy, MD, of MedStar Georgetown University Hospital, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Advertisement
Related to this article

Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.

Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.

T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5




